All, Thanks for the great discussion on Closed Generics earlier today/yesterday. For those that were not able to be on the call, I highly recommend listening to the recording which can be found on the agenda wiki page<https://community.icann.org/x/VqujBg>. The latest version of the Summary Document is here<https://docs.google.com/document/d/1Q6_DxsCvSA_3B7ArncO2U4tWNY3vH7Wi4nINrouR...> (specifically Section 2.7.3 - currently pages 14-20). One of the action items from the call with to create a small sub-group to discuss this issue further to see if it is possible to get a "compromise position" of the Working Group on one of the options that were presented (or any hybrid or new option). We are seeking volunteers to serve on this small group. Please let us know if you would like to sign up for this group. One word of caution: This group is not being set up to rehash the arguments for and against Closed Generics. We have spent more than enough time on that issue and the Summary Documents, combines with the Initial Report and Public Comment Analysis referenced in the Summary Document we believe have effectively captured all of that. What we are looking for is whether there is any solution that can address/mitigate the alleged harms expressed by those that oppose Closed Generics. We are trying to assess whether there is an appetite in the group to compromise. If, after several weeks, we (the Leadership) do not believe there is such an appetite, then we will close the small group down. The last thing we want to do is waste a lot of time discussing an issue that no side is willing to give anymore on. Although you should be familiar with the Summary Document, please do not make any changes to that document at this time (other than glaring errors). The focus should be on finding a compromise (if there is one to be reached). To reiterate, this is a unique situation we have with this issue, because there technically may not be a default position to fall back on. Although it is true that the Board decided to temporarily not allow Closed Generics in 2012<https://www.icann.org/resources/board-material/resolutions-new-gtld-2015-06-...>, the ICANN Board expressly asked the GNSO to create policy on this matter. The Board, in deciding not to temporarily allow closed generics did not expressly endorse any argument for or against closed generics, but rather made it clear that this was an issue for the communti. Therefore, if we cannot agree on a solution, it is not clear what the ICANN Board would ultimately conclude was the default position. It could be the default was not allowing them or, alternatively, the default could be allowing them because the AGB did not indicate a position on this one way or another. Please let us know ASAP if you would like to join this discussion. We will endeavor to get this list up by early next week and try to start discussing the issues right away. Best regards, Jeff Neuman Senior Vice President Com Laude | Valideus 1751 Pinnacle Drive Suite 600, McLean VA 22102, USA M: +1.202.549.5079 D: +1.703.635.7514 E: jeff.neuman@comlaude.com<mailto:jeff.neuman@comlaude.com> www.comlaude.com<http://www.comlaude.com/> [cid:image003.jpg@01D558D6.0CFB5060] ________________________________ The contents of this email and any attachments are confidential to the intended recipient. They may not be disclosed, used by or copied in any way by anyone other than the intended recipient. If you have received this message in error, please return it to the sender (deleting the body of the email and attachments in your reply) and immediately and permanently delete it. Please note that the Com Laude Group does not accept any responsibility for viruses and it is your responsibility to scan or otherwise check this email and any attachments. The Com Laude Group does not accept liability for statements which are clearly the sender's own and not made on behalf of the group or one of its member entities. The Com Laude Group includes Nom-IQ Limited t/a Com Laude, a company registered in England and Wales with company number 5047655 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Valideus Limited, a company registered in England and Wales with company number 06181291 and registered office at 28-30 Little Russell Street, London, WC1A 2HN England; Demys Limited, a company registered in Scotland with company number SC197176, having its registered office at 33 Melville Street, Edinburgh, Lothian, EH3 7JF Scotland; Consonum, Inc. dba Com Laude USA and Valideus USA, headquartered at 1751 Pinnacle Drive, Suite 600, McLean, VA 22102, USA; Com Laude (Japan) Corporation, a company registered in Japan having its registered office at Suite 319,1-3-21 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan. For further information see www.comlaude.com<https://comlaude.com>
